National Bank of Canada FI Raises Holdings in Charles River Laboratories International, Inc. $CRL

National Bank of Canada FI increased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 117.7% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 946,769 shares of the medical research company’s stock after buying an additional 511,901 shares during the period. National Bank of Canada FI’s holdings in Charles River Laboratories International were worth $148,131,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the stock. Neo Ivy Capital Management purchased a new position in shares of Charles River Laboratories International in the 2nd quarter valued at $29,000. Rothschild Investment LLC lifted its stake in shares of Charles River Laboratories International by 82.4% during the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after purchasing an additional 84 shares during the last quarter. Atlantic Union Bankshares Corp purchased a new stake in shares of Charles River Laboratories International during the 3rd quarter worth $31,000. Geneos Wealth Management Inc. boosted its position in Charles River Laboratories International by 98.0% during the second quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 145 shares in the last quarter. Finally, Allworth Financial LP grew its stake in Charles River Laboratories International by 172.7% in the second quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock valued at $45,000 after purchasing an additional 190 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

Shares of CRL stock opened at $151.88 on Tuesday. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $228.88. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.02 and a current ratio of 1.29. The firm has a market capitalization of $7.48 billion, a price-to-earnings ratio of -51.31, a PEG ratio of 2.66 and a beta of 1.64. The stock’s 50-day simple moving average is $190.46 and its 200-day simple moving average is $181.05.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, beating the consensus estimate of $2.33 by $0.06. The firm had revenue of $994.23 million during the quarter, compared to analyst estimates of $986.98 million. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. Charles River Laboratories International’s revenue was down .8% on a year-over-year basis. During the same period last year, the firm posted $2.66 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, equities analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CRL has been the subject of a number of recent research reports. Argus set a $200.00 target price on shares of Charles River Laboratories International in a report on Monday, November 17th. Robert W. Baird set a $193.00 price objective on shares of Charles River Laboratories International in a research report on Thursday, February 19th. UBS Group boosted their price objective on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 25th. Wall Street Zen cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Finally, Bank of America upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 target price for the company in a research note on Monday, December 15th. Ten equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Moderate Buy” and a consensus price target of $203.57.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.